Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 23 Carcinoma, Non-Small-Cell Lung 12 Colorectal Neoplasms 8 Biliary Tract Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Mesothelioma, Malignant 5 Melanoma 5 Liver Neoplasms 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Prostatic Neoplasms 4 Neoplasms 4 Diabetes Mellitus, Insulin-Dependent, 12 4 Neoplasm Metastasis 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Fallopian Tube Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Recurrence 2 Ovarian Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Mesothelioma 2 Gallbladder Neoplasms 2 Endometrial Neoplasms 2 Adenocarcinoma Of Esophagus 2 Vascular Neoplasms 1 Uveal Melanoma 1

Interventions

tremelimumab 1 pembrolizumab 1 enfortumab vedotin 1 durvalumab 1 Watchful Waiting 1 Radiotherapy 1 Palliative Care 1 Drug Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Muscle-invasive Bladder Cancer × tremelimumab × Clear all

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡